Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A01209 | Pages: 175 | Charts: 57 | Tables: 109 |
The global sleep aids market size was valued at $59,815.10 million in 2020, and is projected to reach $111,920.10 million by 2030, registering a CAGR of 6.9% from 2021 to 2030. Sleep disorders are the conditions that impair the sleep pattern or disturb the restful sleep and as a result it can cause daytime sleepiness and other symptoms. It can have several symptoms such as regular experience of difficulty sleeping, tiredness during the day even though sleeping for at least seven hours the night before, reduced or impaired ability to perform regular daytime activities. Not getting enough sleep can have untoward consequences on school &work performance, interpersonal relationships, thinking, mental health, weight and the development of diabetes and heart disease.
The common sleep disorders include insomnia, restless legs syndrome, narcolepsy and sleep apnea. The sleep disorders can be treated with the treatment options such as counseling, medications & supplements like melatonin, zolpidem, zaleplon, eszopiclone, ramelteon, suvorexant, lamborexant, gabapentin, and number of stimulants or wake-promoting medications, such as modafinil, armodafinil and pitolisant. Moreover, regular exercise and proper management of noise, light and temperature at the place also help in sleep impair. Various sleeping aids also can contribute in the treatment of sleep disorders.
Get more information on this report : Request Sample Pages
The growth of the sleep aids market is driven by the benefits of using sleep aids products and rise in disposable income. Moreover, the surge in the geriatric and obese population has led to an increase in the cases of sleep disorder, which is anticipated to increase the patient population with sleep disorders that contribute toward the growth of the market. However, the side effects of sleep aids medication on human health and large number of patent expiration of medication are expected to hinder the sleep aids market growth. Conversely, the advancement of sleep aids product helps to increase the adoption rate and the untapped market in developing economies, which are expected to offer lucrative opportunities for the growth of the market.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Amidst the initial outbreak of COVID-19, the outlook for the sleep aids industry has changed significantly. The COVID-19 pandemic led to the lockdown in the world which resulted in the reduced trade of a number of products, including sleeping aids. This impacted the market by the decreasing the demand of the sleeping aids. Moreover, the disturbances in monthly income of individuals, closure of manufacturing facilities to protect workers in all the regions had reduced the number of production of sleeping aids solutions. The constraints in the handling capacity of goods, at ports, and widespread financial distress also disturbed the supply of the products. It was due to the reason that people feared about the infection during a period of distancing and lockdown. Various regions reported the reduction in the hospital visits.
Overall, the impact of COVID-19 on the sleep aids market was recorded to be fairly negative. This was attributed to decrease in demand of sleeping aids devices for the sleep disorders. Moreover, market players have reduced investment in raw materials and resources, owing to closure of manufacturing facilities to protect workers in all the regions.
[PRODUCTGRAPH]
The sleep aids market is segmented on the basis of product, sleep disorder, and region. By product, the market is segmented into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medications segment is further classified into prescription-based and over-the-counter (OTC) drugs. On the basis of sleep disorders, it is categorized into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleepwalking, and other sleep disorders. Region wise, the sleep aids market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Byproduct, the global sleep aid market is classified into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. Mattress & pillows segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period due to technological advancements in the sleep aid devices, increase in adoption of sleep aid devices, rise in incidence rate of sleep disorders like insomnia, and increase in number of advanced &effective product launches.
[SLEEPDISORDERSGRAPH]
On the basis of sleep disorders, the global sleep aids market is classified into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleepwalking, and other sleep disorders. Insomnia segment was the major contributor to the global sleep aids market in 2020, and is anticipated to remain dominant during the forecast period, due to the increase in healthcare awareness, rise in incidence of sleep apnea, decrease in physical exercise by the population and growth in geriatric population.
North America accounted for major share of the global sleep aids market share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to increase in incidences of Sleep disorders such as sleep apnea, surge in demand for sleep aid devices, availability of advanced healthcare facilities with trained medical professionals, rise in number of R&D activities along with large presence of key players, and surge in investment made by governments in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. Moreover, Japan and China are expected to grow at high CAGR in Asia-Pacific sleep aid market majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced instruments, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of sleep aids.
[REGIONGRAPH]
Key benefits for stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis Top Player Positioning
3.4.1.Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis
CHAPTER 4:SLEEP AIDS MARKET, BY PRODUCT
4.1.Market Overview
4.1.1Market Size and Forecast, By Product
4.2.MATTRESSES & PILLOWS
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region
4.2.3.Market Share Analysis, By Country
4.3.SLEEP LABORATORIES
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region
4.3.3.Market Share Analysis, By Country
4.4.MEDICATIONS
4.4.1.Key Market Trends, Growth Factors and Opportunities
4.4.2.Market Size and Forecast, By Region
4.4.3.Market Share Analysis, By Country
4.4.4.Prescription-based drugs
4.4.4.1.Market Size and Forecast
4.4.5.OTC drugs
4.4.5.1.Market Size and Forecast
4.5.SLEEP APNEA DEVICES
4.5.1.Key Market Trends, Growth Factors and Opportunities
4.5.2.Market Size and Forecast, By Region
4.5.3.Market Share Analysis, By Country
CHAPTER 5:SLEEP AIDS MARKET, BY SLEEP DISORDERS
5.1.Market Overview
5.1.1Market Size and Forecast, By Sleep Disorders
5.2.INSOMNIA
5.2.1.Market Size and Forecast, By Region
5.2.2.Market Share Analysis, By Country
5.3.SLEEP APNEA
5.3.1.Market Size and Forecast, By Region
5.3.2.Market Share Analysis, By Country
5.4.RESTLESS LEGS SYNDROME
5.4.1.Market Size and Forecast, By Region
5.4.2.Market Share Analysis, By Country
5.5.NARCOLEPSY
5.5.1.Market Size and Forecast, By Region
5.5.2.Market Share Analysis, By Country
5.6.SLEEPWALKING
5.6.1.Market Size and Forecast, By Region
5.6.2.Market Share Analysis, By Country
5.7.OTHER SLEEP DISORDERS
5.7.1.Market Size and Forecast, By Region
5.7.2.Market Share Analysis, By Country
CHAPTER 6:SLEEP AIDS MARKET, BY REGION
6.1.Market Overview
6.1.1Market Size and Forecast, By Region
6.2.North America
6.2.1.Key Market Trends and Opportunities
6.2.2.Market Size and Forecast, By Product
6.2.3.Market Size and Forecast, By Sleep Disorders
6.2.4.Market Size and Forecast, By Country
6.2.5.United States Sleep Aids Market
6.2.5.1.Market Size and Forecast, By Product
6.2.5.2.Market Size and Forecast, By Sleep Disorders
6.2.6.Canada Sleep Aids Market
6.2.6.1.Market Size and Forecast, By Product
6.2.6.2.Market Size and Forecast, By Sleep Disorders
6.2.7.Mexico Sleep Aids Market
6.2.7.1.Market Size and Forecast, By Product
6.2.7.2.Market Size and Forecast, By Sleep Disorders
6.3.Europe
6.3.1.Key Market Trends and Opportunities
6.3.2.Market Size and Forecast, By Product
6.3.3.Market Size and Forecast, By Sleep Disorders
6.3.4.Market Size and Forecast, By Country
6.3.5.Germany Sleep Aids Market
6.3.5.1.Market Size and Forecast, By Product
6.3.5.2.Market Size and Forecast, By Sleep Disorders
6.3.6.France Sleep Aids Market
6.3.6.1.Market Size and Forecast, By Product
6.3.6.2.Market Size and Forecast, By Sleep Disorders
6.3.7.Uk Sleep Aids Market
6.3.7.1.Market Size and Forecast, By Product
6.3.7.2.Market Size and Forecast, By Sleep Disorders
6.3.8.Italy Sleep Aids Market
6.3.8.1.Market Size and Forecast, By Product
6.3.8.2.Market Size and Forecast, By Sleep Disorders
6.3.9.Spain Sleep Aids Market
6.3.9.1.Market Size and Forecast, By Product
6.3.9.2.Market Size and Forecast, By Sleep Disorders
6.3.10.Rest Of Europe Sleep Aids Market
6.3.10.1.Market Size and Forecast, By Product
6.3.10.2.Market Size and Forecast, By Sleep Disorders
6.4.Asia-Pacific
6.4.1.Key Market Trends and Opportunities
6.4.2.Market Size and Forecast, By Product
6.4.3.Market Size and Forecast, By Sleep Disorders
6.4.4.Market Size and Forecast, By Country
6.4.5.Japan Sleep Aids Market
6.4.5.1.Market Size and Forecast, By Product
6.4.5.2.Market Size and Forecast, By Sleep Disorders
6.4.6.China Sleep Aids Market
6.4.6.1.Market Size and Forecast, By Product
6.4.6.2.Market Size and Forecast, By Sleep Disorders
6.4.7.Australia Sleep Aids Market
6.4.7.1.Market Size and Forecast, By Product
6.4.7.2.Market Size and Forecast, By Sleep Disorders
6.4.8.India Sleep Aids Market
6.4.8.1.Market Size and Forecast, By Product
6.4.8.2.Market Size and Forecast, By Sleep Disorders
6.4.9.South Korea Sleep Aids Market
6.4.9.1.Market Size and Forecast, By Product
6.4.9.2.Market Size and Forecast, By Sleep Disorders
6.4.10.Rest Of Asia-pacific Sleep Aids Market
6.4.10.1.Market Size and Forecast, By Product
6.4.10.2.Market Size and Forecast, By Sleep Disorders
6.5.LAMEA
6.5.1.Key Market Trends and Opportunities
6.5.2.Market Size and Forecast, By Product
6.5.3.Market Size and Forecast, By Sleep Disorders
6.5.4.Market Size and Forecast, By Country
6.5.5.Brazil Sleep Aids Market
6.5.5.1.Market Size and Forecast, By Product
6.5.5.2.Market Size and Forecast, By Sleep Disorders
6.5.6.Saudi Arabia Sleep Aids Market
6.5.6.1.Market Size and Forecast, By Product
6.5.6.2.Market Size and Forecast, By Sleep Disorders
6.5.7.South Africa Sleep Aids Market
6.5.7.1.Market Size and Forecast, By Product
6.5.7.2.Market Size and Forecast, By Sleep Disorders
6.5.8.Rest of LAMEA Sleep Aids Market
6.5.8.1.Market Size and Forecast, By Product
6.5.8.2.Market Size and Forecast, By Sleep Disorders
CHAPTER 7:COMPANY PROFILES
7.1.Cadwell Industries, Inc.
7.1.1.Company Overview
7.1.2.Key Executives
7.1.3.Company snapshot
7.1.4.Operating business segments
7.1.5.Product portfolio
7.1.6.Business Performance
7.1.7.Key Strategic Moves and Developments
7.2.Compumedics Limited
7.2.1.Company Overview
7.2.2.Key Executives
7.2.3.Company snapshot
7.2.4.Operating business segments
7.2.5.Product portfolio
7.2.6.Business Performance
7.2.7.Key Strategic Moves and Developments
7.3.Drive DeVilbiss Healthcare Inc.
7.3.1.Company Overview
7.3.2.Key Executives
7.3.3.Company snapshot
7.3.4.Operating business segments
7.3.5.Product portfolio
7.3.6.Business Performance
7.3.7.Key Strategic Moves and Developments
7.4.GlaxoSmithKline Plc
7.4.1.Company Overview
7.4.2.Key Executives
7.4.3.Company snapshot
7.4.4.Operating business segments
7.4.5.Product portfolio
7.4.6.Business Performance
7.4.7.Key Strategic Moves and Developments
7.5.Merck And Co., Inc.
7.5.1.Company Overview
7.5.2.Key Executives
7.5.3.Company snapshot
7.5.4.Operating business segments
7.5.5.Product portfolio
7.5.6.Business Performance
7.5.7.Key Strategic Moves and Developments
7.6.Natus Medical Inc.
7.6.1.Company Overview
7.6.2.Key Executives
7.6.3.Company snapshot
7.6.4.Operating business segments
7.6.5.Product portfolio
7.6.6.Business Performance
7.6.7.Key Strategic Moves and Developments
7.7.Koninklijke Philips N.V.
7.7.1.Company Overview
7.7.2.Key Executives
7.7.3.Company snapshot
7.7.4.Operating business segments
7.7.5.Product portfolio
7.7.6.Business Performance
7.7.7.Key Strategic Moves and Developments
7.8.PFIZER, INC.
7.8.1.Company Overview
7.8.2.Key Executives
7.8.3.Company snapshot
7.8.4.Operating business segments
7.8.5.Product portfolio
7.8.6.Business Performance
7.8.7.Key Strategic Moves and Developments
7.9.Sanofi S.A.
7.9.1.Company Overview
7.9.2.Key Executives
7.9.3.Company snapshot
7.9.4.Operating business segments
7.9.5.Product portfolio
7.9.6.Business Performance
7.9.7.Key Strategic Moves and Developments
7.10.SleepMed Inc.
7.10.1.Company Overview
7.10.2.Key Executives
7.10.3.Company snapshot
7.10.4.Operating business segments
7.10.5.Product portfolio
7.10.6.Business Performance
7.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL SLEEP AIDS MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 2.GLOBAL SLEEP AIDS MARKET FOR MATTRESSES & PILLOWS, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL SLEEP AIDS MARKET FOR SLEEP LABORATORIES, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL SLEEP AIDS MARKET FOR MEDICATIONS, BY REGION, 2020-2030 ($MILLION)
TABLE 5.GLOBAL SLEEP AIDS MARKET FOR SLEEP APNEA DEVICES, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL SLEEP AIDS MARKET, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 7.GLOBAL SLEEP AIDS MARKET FOR INSOMNIA, BY REGION, 2020-2030 ($MILLION)
TABLE 8.GLOBAL SLEEP AIDS MARKET FOR SLEEP APNEA, BY REGION, 2020-2030 ($MILLION)
TABLE 9.GLOBAL SLEEP AIDS MARKET FOR RESTLESS LEGS SYNDROME, BY REGION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL SLEEP AIDS MARKET FOR NARCOLEPSY, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL SLEEP AIDS MARKET FOR SLEEPWALKING, BY REGION, 2020-2030 ($MILLION)
TABLE 12.GLOBAL SLEEP AIDS MARKET FOR OTHER SLEEP DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL SLEEP AIDS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14.NORTH AMERICA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 15.NORTH AMERICA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 16.UNITED STATES SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 17.UNITED STATES SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 18.CANADA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 19.CANADA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 20.MEXICO SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 21.MEXICO SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 22.EUROPE SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 23.EUROPE SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 24.GERMANY SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25.GERMANY SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 26.FRANCE SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 27.FRANCE SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 28.UK SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29.UK SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 30.ITALY SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 31.ITALY SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 32.SPAIN SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 33.SPAIN SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 34.REST OF EUROPE SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 35.REST OF EUROPE SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 36.ASIA-PACIFIC SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 37.ASIA-PACIFIC SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 38.JAPAN SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 39.JAPAN SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 40.CHINA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41.CHINA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 42.AUSTRALIA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 43.AUSTRALIA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 44.INDIA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 45.INDIA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 46.SOUTH KOREA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 47.SOUTH KOREA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 50.LAMEA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 51.LAMEA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 52.BRAZIL SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53.BRAZIL SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 54.SAUDI ARABIA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 55.SAUDI ARABIA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 56.SOUTH AFRICA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 57.SOUTH AFRICA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 58.REST OF LAMEA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 59.REST OF LAMEA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
TABLE 60.CADWELL INDUSTRIES, INC.: KEY EXECUTIVES
TABLE 61.CADWELL INDUSTRIES, INC.: COMPANY SNAPSHOT
TABLE 62.CADWELL INDUSTRIES, INC.: OPERATING SEGMENTS
TABLE 63.CADWELL INDUSTRIES, INC.: PRODUCT PORTFOLIO
TABLE 64.CADWELL INDUSTRIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 65.COMPUMEDICS LIMITED: KEY EXECUTIVES
TABLE 66.COMPUMEDICS LIMITED: COMPANY SNAPSHOT
TABLE 67.COMPUMEDICS LIMITED: OPERATING SEGMENTS
TABLE 68.COMPUMEDICS LIMITED: PRODUCT PORTFOLIO
TABLE 69.COMPUMEDICS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70.DRIVE DEVILBISS HEALTHCARE INC.: KEY EXECUTIVES
TABLE 71.DRIVE DEVILBISS HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 72.DRIVE DEVILBISS HEALTHCARE INC.: OPERATING SEGMENTS
TABLE 73.DRIVE DEVILBISS HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 74.DRIVE DEVILBISS HEALTHCARE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 75.GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 76.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 77.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 78.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 79.GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 80.MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 81.MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 82.MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 83.MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 84.MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 85.NATUS MEDICAL INC.: KEY EXECUTIVES
TABLE 86.NATUS MEDICAL INC.: COMPANY SNAPSHOT
TABLE 87.NATUS MEDICAL INC.: OPERATING SEGMENTS
TABLE 88.NATUS MEDICAL INC.: PRODUCT PORTFOLIO
TABLE 89.NATUS MEDICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
TABLE 91.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 92.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
TABLE 93.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 94.KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95.PFIZER, INC.: KEY EXECUTIVES
TABLE 96.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 97.PFIZER, INC.: OPERATING SEGMENTS
TABLE 98.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 99.PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100.SANOFI S.A.: KEY EXECUTIVES
TABLE 101.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 102.SANOFI S.A.: OPERATING SEGMENTS
TABLE 103.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 104.SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.SLEEPMED INC.: KEY EXECUTIVES
TABLE 106.SLEEPMED INC.: COMPANY SNAPSHOT
TABLE 107.SLEEPMED INC.: OPERATING SEGMENTS
TABLE 108.SLEEPMED INC.: PRODUCT PORTFOLIO
TABLE 109.SLEEPMED INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL SLEEP AIDS MARKET SEGMENTATION
FIGURE 2.GLOBAL SLEEP AIDS MARKET
FIGURE 3.SEGMENTATION SLEEP AIDS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN SLEEP AIDS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: SLEEP AIDS MARKET
FIGURE 16.SLEEP AIDS MARKET SEGMENTATION, BY PRODUCT
FIGURE 17.SLEEP AIDS MARKET FOR MATTRESSES & PILLOWS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.SLEEP AIDS MARKET FOR SLEEP LABORATORIES, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.SLEEP AIDS MARKET FOR MEDICATIONS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 20.SLEEP AIDS MARKET FOR SLEEP APNEA DEVICES, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.SLEEP AIDS MARKET SEGMENTATION, BY SLEEP DISORDERS
FIGURE 22.SLEEP AIDS MARKET FOR INSOMNIA, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 23.SLEEP AIDS MARKET FOR SLEEP APNEA, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 24.SLEEP AIDS MARKET FOR RESTLESS LEGS SYNDROME, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 25.SLEEP AIDS MARKET FOR NARCOLEPSY, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.SLEEP AIDS MARKET FOR SLEEPWALKING, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 27.SLEEP AIDS MARKET FOR OTHER SLEEP DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 28.CADWELL INDUSTRIES, INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 29.CADWELL INDUSTRIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 30.CADWELL INDUSTRIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31.COMPUMEDICS LIMITED: NET SALES, 2018-2020 ($MILLION)
FIGURE 32.COMPUMEDICS LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33.COMPUMEDICS LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34.DRIVE DEVILBISS HEALTHCARE INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 35.DRIVE DEVILBISS HEALTHCARE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 36.DRIVE DEVILBISS HEALTHCARE INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 37.GLAXOSMITHKLINE PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 38.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.MERCK AND CO., INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 41.MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.NATUS MEDICAL INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 44.NATUS MEDICAL INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.NATUS MEDICAL INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 46.KONINKLIJKE PHILIPS N.V.: NET SALES, 2018-2020 ($MILLION)
FIGURE 47.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 49.PFIZER, INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 50.PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.PFIZER, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 52.SANOFI S.A.: NET SALES, 2018-2020 ($MILLION)
FIGURE 53.SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 54.SANOFI S.A.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 55.SLEEPMED INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 56.SLEEPMED INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 57.SLEEPMED INC.: REVENUE SHARE, BY REGION, 2020 (%)